Quantcast

The reducing end of αGal oligosaccharides contributes to their efficiency in blocking natural antibodies of human and baboon sera

Research paper by Francisca A. Neethling, David Joziasse, Nicolai Bovin, David K. C. Cooper, Rafael Oriol

Indexed on: 01 Mar '96Published on: 01 Mar '96Published in: Transplant International



Abstract

Synthetic galactosyl oligosaccharides were tested for their ability to inhibit the cytotoxic reaction of human and baboon natural antibodies on PK15 cells in culture. Methyl-α-Gal gave weak inhibition, Galα1-3Gal substantially inhibited the reaction (400 μM), and Galα1-3Galβ2-4GlcNAc was ten times more efficient (30 μM). The modification from α to β anomeric configuration of the nonreducing end resulted in a complete loss of activity, while substitutions at the reducing end induced only a partial loss of activity. These observations suggest that natural anti-αGal antibodies recognize the epitope from its nonreducing end, but that substitutions at the reducing terminus can modify the antibody-binding capacity. Modified tri- and tetrasaccharides are better inhibitors than the disaccharide but not as good as Galα1-3Galβ1-4GlcNAc. The reducing terminus therefore contributes some energy to the reaction, indicating that certain oligosaccharides will be of more potential clinical use than others.